Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
Husam Abdel-QadirNasruddin SabrieDarryl P LeongAndrea PangPeter C AustinAnca PricaKumaraswamy NanthakumarOscar Calvillo-ArgüellesDouglas S LeePaaladinesh ThavendiranathanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Ibrutinib is associated with higher risk of AF, bleeding, and HF, but not AMI or stroke.